Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MoTriColor vinorelbine in advanced BRAF-like colon cancer
NL-OMON47411Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of vinorelbine in colon cancer and colon adenocarcinoma (2 cohorts), sponsored by Netherlands Cancer Institute. Primary endpoint: Progression-free survival at 6 weeks. Started Oct 2018; status: active, not recruiting.
02
Drugs
vinorelbine
03
Conditions
colon cancercolon adenocarcinoma
Beyond the preview
Go deeper on NL-OMON47411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47411.